Turning Real-World Evidence into Real-World Impact

Speakers

• 

  Farah Husein Director Science and Methods, Canada’s Drug Agency
  

  Farah Husein

  Director Science and Methods, Canada’s Drug Agency

  Director, Science and Methods, Canada’s Drug Agency (formerly CADTH). Senior strategic Leader and people manager, with deep experience in HTA, the pharmaceutical industry and health care settings.

• 

  Jennifer Glass RWE Lead Canada, Medical Affairs, Eli Lilly
  

  Jennifer Glass

  RWE Lead Canada, Medical Affairs, Eli Lilly

  Jennifer is a Real World Evidence Lead at Lilly Canada with 20 years of experience in the pharmaceutical industry, specializing in health outcomes research, health economics, and market access. Her current role leverages expertise in health economics and outcomes research (HEOR) design and integrated evidence generation planning. She has held previous roles in Pricing and Reimbursement, PSP leadership, and managed a consulting team focusing on Health Outcomes and Access, in addition to previous HEOR execution roles. Jennifer graduated from the University of Toronto Faculty of Pharmaceutical Sciences with a PhD in Outcomes Research in the field of Clinical Neuroscience.

• 

  John Burrows Vice President Rare Disease, Novo Nordisk
  

  John Burrows

  Vice President Rare Disease, Novo Nordisk

  John has spent the last 37 years working in all func􀆟onal areas of pharma in Canada. He has worked in 12
  therapeu􀆟c areas covering acute, chronic, and rare diseases. John has led the Rare Disease func􀆟on on the Novo
  Nordisk Execu􀆟ve team for the last 11 years.

• 

  Laurie Wingett Director, Business Development, IQVIA
  

  Laurie Wingett

  Director, Business Development, IQVIA

  I am passionate about creating and implementing strategies that meet patient, health care professional, market access, regulator and brand needs. I thrive in an environment where I can fully utilize my transformational leadership skills. I enjoy uncovering win win opportunities and building strong stakeholder relationships through the achievement of our common goals.

• 

  Ryan Lock Director, Federal Affairs, Policy and Public Health, GSK
  

  Ryan Lock

  Director, Federal Affairs, Policy and Public Health, GSK

  Ryan W. Lock is Director, Sr. Federal Affairs and Public Policy for GSK Canada. Leading a small team within GSK’s Government Affairs and Market Access department, Ryan is responsible for developing GSK policy positions on market access and reimbursement issues and implementing evidence-driven national advocacy campaigns.

  Ryan is also responsible for GSK’s publicly-tendered vaccines portfolio, which includes managing relationships with the Public Health Agency of Canada and provincial public health departments.

  Prior to joining GSK in February 2016, Ryan was a member of the Ontario Public Service for sixteen years, including over ten years at the senior management level. His varied roles included Director of the Access to Capital and Business Development Branch for the Ministry of Research and Innovation; Director of Strategic Policy for the Ministry of Consumer and Business Services; and Director of the Office for Social Enterprise with the Ministry of Economic Development, Employment and Infrastructure.

  Ryan has extensive policy experience, both in industry and in government. In industry, Ryan was active in helping to shape and inform Ontario’s Bill 160 health transparency legislation. During his time with the Ontario Government, working closely with industry and other key stakeholders, Ryan led the development of leading-edge policies, programs and marketing initiatives to help reinforce Ontario’s position as a Top Five life sciences cluster internationally.